Brain and Central Nervous System Tumors
Conditions
Keywords
adult grade I meningioma, adult grade II meningioma, adult grade III meningioma, adult anaplastic meningioma, adult papillary meningioma, recurrent adult brain tumor
Brief summary
RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy, may kill more tumor cells and cause less damage to normal tissue. It is not yet known whether observation is more effective than radiation therapy in treating patients with meningioma. PURPOSE: This phase II trial is studying observation to see how well it works compared with radiation therapy in treating patients with grade I, grade II, or grade III meningioma.
Detailed description
OBJECTIVES: Primary * To estimate the rates of progression-free survival at 3 years in patients with low-risk meningioma undergoing observation and in patients with intermediate- or high-risk meningioma undergoing radiotherapy. Secondary * To study the concordance, or lack thereof, between central and parent institution histopathologic diagnosis, grading, and subtyping. * To estimate the rates of overall survival at 3 years in these patients. * To estimate the incidence rates of acute and late adverse events ≥ grade 2 in patients with intermediate- or high-risk meningioma undergoing radiotherapy. * To evaluate MRI imaging predictors by central neuroradiology review at diagnosis, at any failure, and at 3 years. * To evaluate adherence to protocol-specific target and normal tissue radiotherapy parameters. This is a multicenter study. Patients are assigned to 1 of 3 groups according to risk. After completion of study treatment, patients are followed up every 3-6 months for 3 years and then annually for 10 years.
Interventions
RADIATION54 Gy radiotherapy
External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
RADIATION60 Gy radiotherapy
External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
Sponsors
National Cancer Institute (NCI)
NRG Oncology
Radiation Therapy Oncology Group
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. A histologically documented World Health Organization (WHO) grade I, II, or III meningioma, newly diagnosed or recurrent, and of any resection extent, confirmed by central pathology review. Patients are partitioned according to three groupings: Group I (low risk), Group II (intermediate risk), and Group III (high risk) as defined below: * Group I (low risk): Patients with a newly diagnosed WHO grade I meningioma that has been gross totally resected (Simpson's grade I, II, or III resections, with no residual nodular enhancement on postoperative imaging) or subtotally resected (residual nodular enhancement or Simpson grade IV or V excision). The extent of resection will be based upon the neurosurgeons' assessment and postoperative MR imaging. * Group II (intermediate risk): Patients with a newly diagnosed gross totally resected WHO grade II meningioma or patients with a recurrent WHO grade I meningioma irrespective of the resection extent. Resection extent will be recorded on the same basis described above for the low-risk group. * Group III (high risk): Patients with a newly diagnosed or a recurrent WHO grade III meningioma of any resection extent; patients with a recurrent WHO grade II meningioma of any resection extent; or patients with a newly diagnosed subtotally resected WHO grade II meningioma. In the setting of a newly diagnosed meningioma, the histologic diagnosis must have been reached within 6 months of Step 2 registration. Resection extent will be recorded on the same basis described above for the low-risk group. * 1.1 In the setting of a newly diagnosed meningioma, the histologic diagnosis must have been reached within 24 weeks prior to Step 2 registration. In the setting of a recurrent meningioma, there are no such time constraints. Additional resection or biopsy is encouraged for patients with recurrence but is not requisite. If further biopsy or resection is performed at recurrence, these specimens must be submitted; submission of the original pathology specimens is encouraged but not required. The diagnosis of recurrence solely on the basis of imaging findings is permitted, but if no additional resection is performed, specimens from prior resection must be submitted. * 1.2 In cases of newly diagnosed or surgically treated recurrent meningioma, the operating neurosurgeon must provide a Simpson grade for the degree of resection. 2. History/physical examination, including neurologic examination, within 8 weeks prior to Step 2 registration 3. Zubrod Performance Status 0-1 4. Age ≥ 18 5. All patients must have a magnetic resonance imaging (MRI) scan within 12 weeks prior to Step 2 registration. Both preoperative and postoperative MRIs are required for all newly diagnosed patients in groups I, II, or III. In the setting of group II or III patients with recurrent/progressive meningioma and without recent surgery, a pre-operative study may not apply, although MRI documentation of recurrence or progression is required. MRIs must include precontrast T1, T2, and flair images and multiplanar (axial, sagittal, and coronal) postcontrast T1. The postoperative study must be completed within 12 weeks of surgery. * 5.1 Group I: All group I patients will have surgery. Preoperative and postoperative MRIs are thus required in order to assess resection extent. * 5.2 Group II: Surgery will be undertaken for the subgroup with a gross totally resected WHO grade II meningioma. For these patients preoperative and postoperative MRIs are necessitated. For the other subgroup with recurrent WHO grade I meningioma, preoperative and postoperative MRIs are required if surgery is undertaken for the recurrent/progressive tumor. However, only the follow-up imaging documenting recurrence or progression will apply if further surgery is not completed. * 5.3 Group III: Surgery will be undertaken for the subgroup with a newly diagnosed WHO grade III meningioma. For these patients preoperative and postoperative MRIs are obligatory. For the subgroups with recurrent WHO grade II or III meningioma, preoperative and postoperative MRIs are required if surgery is undertaken for the recurrent/progressive tumor. However, only the follow-up imaging documenting recurrence or progression will apply if further surgery is not completed. 6. For woman of childbearing potential who are intermediate or high risk: * 6.1 Negative serum pregnancy test within 14 days prior to Step 2 registration * 6.2 The patient must agree to practice adequate contraception from the time of the negative serum pregnancy test throughout the entire course of EBRT. 7. Patient must sign study-specific informed consent prior to study entry
Exclusion criteria
1. Extracranial meningioma 2. Multiple meningiomas 3. Hemangiopericytoma 4. Major medical illnesses or psychiatric impairments which, in the investigators opinion, will prevent administration or completion of the protocol therapy or preclude informed consent 5. Previous radiation therapy to the scalp, cranium, brain, or skull base 6. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) 7. Patients with severe, active comorbidity including, but not restricted to: * 7.1 Unstable angina and/or congestive heart failure requiring hospitalization at the time of Step 2 registration * 7.2 Transmural myocardial infarction within the last 6 months * 7.3 Acute bacterial or fungal infection requiring intravenous antibiotics at the time of Step 2 registration * 7.4 Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of Step 2 registration * 7.5 Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects. Note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol. * 7.6 Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. * 7.7 Active connective tissue disorders such as lupus or scleroderma if the patient is intermediate or high risk 8. Inability to receive gadolinium
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival Rate at 3 Years | From registration to 3 years | Progression was determined by central review of magnetic resonance imaging (MRI) exams and is defined as an increase in measurable tumor of greater than 20% in any diameter, or as new nodular enhancement in patients with no measurable tumor on initial postoperative imaging. In the absence of neurologic progression (NP), suspected imaging progression of less than 5 mm (maximum diameter) must be confirmed on two successive follow-up MRI studies, a minimum of 3 months apart. NP is defined as a new or progressive neurologic deficit attributed to the meningioma, with or without measurable meningioma growth. Progression-free survival (PFS) rates are estimated using the binomial method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ninety-one days from start of radiation therapy to last follow-up. Maximum follow-up at time of analysis was 6.3 years. | Grades 2-5 neurology, ocular/visual, dermatologic/skin \[excluding alopecia\] categories, individually and combined for acute adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 where the attribution is related to treatment as definite, probable, possible, or unknown. Late adverse events are those occurring more than 90 days from start of radiation therapy. |
| Overall Survival Rate at 3 Years | From registration to 3 years | Overall survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. |
| Progression-free Survival Rate at 3 Years (Kaplan-Meier Method) | From registration to 3 years | Progression was determined by central review of MRI exams and is defined as an increase in measurable tumor of greater than 20% in any diameter, or as new nodular enhancement in patients with no measurable tumor on initial postoperative imaging. In the absence of neurologic progression (NP), suspected imaging progression of less than 5 mm (maximum diameter) must be confirmed on two successive follow-up MRI studies, a minimum of 3 months apart. NP is defined as a new or progressive neurologic deficit attributed to the meningioma, with or without measurable meningioma growth. Progression-free survival time is defined as time from registration to the date of progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. |
| Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Baseline, at time of first progression, and at 3 years | MRI's were centrally reviewed by the study neuroradiology co-chairs for presence of edema, homogeneous enhancement, calcification, hyperostosis, and brain invasion. Data is presented for all risk groups combined, with time points presented in each column. Neither risk groups nor time points are compared. |
| Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | From start of radiation to 90 days. | Grades 2-5 neurology, ocular/visual, dermatologic/skin \[excluding alopecia\] categories, individually and combined for acute adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 where the attribution is related to treatment as definite, probable, possible, or unknown. Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. |
| Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | After treatment delivery | The principle investigator performed a radiotherapy quality assurance (QA) review. |
| Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Baseline | A pathology review was conducted both by the institution and centrally, with three possible choices for grade / subtype: World Health Organization (WHO) Grade I / benign; WHO grade II / atypical; WHO grade III / anaplastic. Data is presented for all risk groups combined. |
| Molecular Correlative Studies | From registration to 3 years | — |
| Histopathologic Correlates of PFS Including Light Microscopy, Immunohistochemical Analysis, and Microarray Analysis | From registration to 3 years | — |
| Greatest Single Dimension From MRI as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Baseline, at time of first progression, and at 3 years | MRI's were centrally reviewed by the study neuroradiology co-chairs. Data is presented for all risk groups combined, with time points presented in each column. Neither risk groups nor time points are compared. |
Countries
Canada, United States
Participant flow
Pre-assignment details
Two hundred forty-four patients registered for the first step registration which consisted of central pathology review confirmation of histology. One hundred seventy-eight continued on to the second step registration.
Participants by arm
| Arm | Count |
|---|---|
| Low Risk No treatment given | 60 |
| Intermidiate Risk 54 Gy radiotherapy | 52 |
| High Risk 60 Gy radiotherapy | 53 |
| Total | 165 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Protocol Violation | 5 | 4 | 4 |
Baseline characteristics
| Characteristic | Low Risk | Intermidiate Risk | High Risk | Total |
|---|---|---|---|---|
| Age, Continuous | 56 years | 53 years | 62 years | 56 years |
| Sex: Female, Male Female | 48 Participants | 32 Participants | 28 Participants | 108 Participants |
| Sex: Female, Male Male | 12 Participants | 20 Participants | 25 Participants | 57 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 22 / 60 | 47 / 52 | 47 / 53 |
| other Total, other adverse events | 22 / 60 | 47 / 52 | 47 / 53 |
| serious Total, serious adverse events | 0 / 60 | 1 / 52 | 5 / 53 |
Outcome results
Primary
Progression-free Survival Rate at 3 Years
Progression was determined by central review of magnetic resonance imaging (MRI) exams and is defined as an increase in measurable tumor of greater than 20% in any diameter, or as new nodular enhancement in patients with no measurable tumor on initial postoperative imaging. In the absence of neurologic progression (NP), suspected imaging progression of less than 5 mm (maximum diameter) must be confirmed on two successive follow-up MRI studies, a minimum of 3 months apart. NP is defined as a new or progressive neurologic deficit attributed to the meningioma, with or without measurable meningioma growth. Progression-free survival (PFS) rates are estimated using the binomial method.
Time frame: From registration to 3 years
Population: Eligible patients who started study treatment and evaluable for 3-year progression-free survival
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Low Risk | Progression-free Survival Rate at 3 Years | 92.2 percentage of participants |
| Intermidiate Risk | Progression-free Survival Rate at 3 Years | 93.7 percentage of participants |
| High Risk | Progression-free Survival Rate at 3 Years | 58.8 percentage of participants |
Secondary
Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters
The principle investigator performed a radiotherapy quality assurance (QA) review.
Time frame: After treatment delivery
Population: Eligible participants who started treatment and were centrally reviewed
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Per protocol | 36 Participants |
| Low Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Acceptable variation | 4 Participants |
| Low Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Unacceptable deviation | 2 Participants |
| Low Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Not evaluable | 2 Participants |
| Intermidiate Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Not evaluable | 1 Participants |
| Intermidiate Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Per protocol | 39 Participants |
| Intermidiate Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Unacceptable deviation | 1 Participants |
| Intermidiate Risk | Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters | Acceptable variation | 5 Participants |
Secondary
Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping
A pathology review was conducted both by the institution and centrally, with three possible choices for grade / subtype: World Health Organization (WHO) Grade I / benign; WHO grade II / atypical; WHO grade III / anaplastic. Data is presented for all risk groups combined.
Time frame: Baseline
Population: Eligible patients with central and site reviews
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Atypical | 2 Participants |
| Low Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Benign | 74 Participants |
| Low Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Anaplastic | 0 Participants |
| Intermidiate Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Atypical | 60 Participants |
| Intermidiate Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Benign | 9 Participants |
| Intermidiate Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Anaplastic | 2 Participants |
| High Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Benign | 1 Participants |
| High Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Anaplastic | 16 Participants |
| High Risk | Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping | Site Review: Atypical | 8 Participants |
Comparison: The Kappa (κ) coefficient was used to assess the measure of agreement between the reviewers. κ can be interpreted as follows (κ / Agreement):~\< 0 / Less than chance agreement; 0.01-0.20 / Slight agreement; 0.21-0.40 / Fair agreement; 0.41-0.60 / Moderate agreement; 0.61-0.80 / Substantial agreement; 0.81-0.99 / Almost perfect agreement.~The asymptotic test of the null hypothesis: κ=0 will be performed using the Z-statistic to determine the strength of agreement.p-value: <0.000195% CI: [0.71, 0.87]Z test
Secondary
Greatest Single Dimension From MRI as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years
MRI's were centrally reviewed by the study neuroradiology co-chairs. Data is presented for all risk groups combined, with time points presented in each column. Neither risk groups nor time points are compared.
Time frame: Baseline, at time of first progression, and at 3 years
Population: Eligible participants who started study treatment, had a centrally reviewed MRI at the given time, and whose MRI was evaluable for tumor dimension.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Low Risk | Greatest Single Dimension From MRI as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | 42.7 milimeters |
| Intermidiate Risk | Greatest Single Dimension From MRI as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | 34.7 milimeters |
| High Risk | Greatest Single Dimension From MRI as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | 29.0 milimeters |
Secondary
Histopathologic Correlates of PFS Including Light Microscopy, Immunohistochemical Analysis, and Microarray Analysis
Time frame: From registration to 3 years
Population: The protocol did not provide sufficient detail to meet National Cancer Institute requirements for release of specimens from the NRG tissue bank for the protocol-specified analysis, therefore no assays were performed and no data were collected for this outcome measure. Specimen use will require federal approval and funding separate from this trial.
Secondary
Molecular Correlative Studies
Time frame: From registration to 3 years
Population: The protocol did not provide sufficient detail to meet National Cancer Institute requirements for release of specimens from the NRG Oncology tissue bank for the protocol-specified analysis, therefore no assays were performed and no data were collected for this outcome measure. Specimen use will require federal approval and funding separate from this trial.
Secondary
Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years
MRI's were centrally reviewed by the study neuroradiology co-chairs for presence of edema, homogeneous enhancement, calcification, hyperostosis, and brain invasion. Data is presented for all risk groups combined, with time points presented in each column. Neither risk groups nor time points are compared.
Time frame: Baseline, at time of first progression, and at 3 years
Population: Eligible participants who started study treatment, had a centrally reviewed MRI at the given time, and whose MRI was evaluable for the given feature
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Hyperostosis | 17 Participants |
| Low Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Calcification | 6 Participants |
| Low Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Edema | 76 Participants |
| Low Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Homogeneous Enhancement | 88 Participants |
| Low Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Brain Invasion | 1 Participants |
| Intermidiate Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Calcification | 0 Participants |
| Intermidiate Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Edema | 13 Participants |
| Intermidiate Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Homogeneous Enhancement | 9 Participants |
| Intermidiate Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Hyperostosis | 0 Participants |
| Intermidiate Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Brain Invasion | 0 Participants |
| High Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Brain Invasion | 1 Participants |
| High Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Hyperostosis | 1 Participants |
| High Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Edema | 15 Participants |
| High Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Calcification | 1 Participants |
| High Risk | Number of Participants Determined to Have MRI Imaging Features as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years | Homogeneous Enhancement | 14 Participants |
Secondary
Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia]
Grades 2-5 neurology, ocular/visual, dermatologic/skin \[excluding alopecia\] categories, individually and combined for acute adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 where the attribution is related to treatment as definite, probable, possible, or unknown. Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.
Time frame: From start of radiation to 90 days.
Population: Eligible patients who started study treatment with acute AE assessed. Low risk patients are not reported since they did not receive any study treatment.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 2 | 4 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | None Grade 2-5 | 42 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 2 | 1 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | None Grade 2-5 | 45 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 2 | 1 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | None Grade 2-5 | 45 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 2 | 5 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | None Grade 2-5 | 41 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 2 | 2 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 2 | 3 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 2 | 4 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 3 | 2 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 3 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 5 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | None Grade 2-5 | 47 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | None Grade 2-5 | 48 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 2 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 3 | 2 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 3 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 5 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 5 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 5 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | None Grade 2-5 | 51 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Acute Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | None Grade 2-5 | 53 Participants |
Secondary
Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia]
Grades 2-5 neurology, ocular/visual, dermatologic/skin \[excluding alopecia\] categories, individually and combined for acute adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 where the attribution is related to treatment as definite, probable, possible, or unknown. Late adverse events are those occurring more than 90 days from start of radiation therapy.
Time frame: Ninety-one days from start of radiation therapy to last follow-up. Maximum follow-up at time of analysis was 6.3 years.
Population: Eligible patients who started study treatment with acute AE assessed. Low risk patients are not reported since they did not receive any study treatment.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 2 | 12 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | None Grade 2-5 | 39 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 2 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | None Grade 2-5 | 51 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 2 | 1 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | None Grade 2-5 | 50 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 2 | 13 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 3 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 4 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 5 | 0 Participants |
| Low Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | None Grade 2-5 | 38 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 2 | 11 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 2 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 3 | 3 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 2 | 11 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 3 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | Grade 5 | 1 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | None Grade 2-5 | 36 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Neurology | None Grade 2-5 | 36 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 2 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 3 | 3 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 3 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | Grade 5 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 4 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Groups combined | Grade 5 | 1 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | Grade 5 | 0 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Dermatology/Skin | None Grade 2-5 | 51 Participants |
| Intermidiate Risk | Number of Patients With Grades 2-5 Late Adverse Events in the Following Categories Individually and Combined: Neurology, Ocular/Visual, Dermatologic/Skin [Excluding Alopecia] | Ocular/visual | None Grade 2-5 | 51 Participants |
Secondary
Overall Survival Rate at 3 Years
Overall survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.
Time frame: From registration to 3 years
Population: Eligible patients who started study treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Low Risk | Overall Survival Rate at 3 Years | 98.1 percentage of participants |
| Intermidiate Risk | Overall Survival Rate at 3 Years | 95.8 percentage of participants |
| High Risk | Overall Survival Rate at 3 Years | 78.4 percentage of participants |
Secondary
Progression-free Survival Rate at 3 Years (Kaplan-Meier Method)
Progression was determined by central review of MRI exams and is defined as an increase in measurable tumor of greater than 20% in any diameter, or as new nodular enhancement in patients with no measurable tumor on initial postoperative imaging. In the absence of neurologic progression (NP), suspected imaging progression of less than 5 mm (maximum diameter) must be confirmed on two successive follow-up MRI studies, a minimum of 3 months apart. NP is defined as a new or progressive neurologic deficit attributed to the meningioma, with or without measurable meningioma growth. Progression-free survival time is defined as time from registration to the date of progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method.
Time frame: From registration to 3 years
Population: Eligible patients who started study treatment and evaluable for 3-year progression-free survival
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Low Risk | Progression-free Survival Rate at 3 Years (Kaplan-Meier Method) | 91.4 percentage of participants |
| Intermidiate Risk | Progression-free Survival Rate at 3 Years (Kaplan-Meier Method) | 93.9 percentage of participants |
| High Risk | Progression-free Survival Rate at 3 Years (Kaplan-Meier Method) | 59.2 percentage of participants |